{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:51:50Z","timestamp":1776120710621,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jogc.2026.103237","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:09:07Z","timestamp":1770253747000},"page":"103237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-Agent Gemcitabine in Heavily Pretreated Ovarian Cancer: Experience from a Canadian Tertiary Centre"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4513-2001","authenticated-orcid":false,"given":"Samantha","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raanan","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susie","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Gotlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2026.103237_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jogc.2026.103237_bib2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2026.103237_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.36469\/jheor.2021.29145","article-title":"Real-world treatment patterns, survival, and costs for ovarian cancer in Canada: a retrospective cohort study using provincial administrative data","volume":"8","author":"Hurry","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.jogc.2026.103237_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.jogc.2026.103237_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001813-199512006-00010","article-title":"Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients","volume":"6","author":"Lund","year":"1995","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jogc.2026.103237_bib6","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2026.103237_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jogc.2026.103237_bib8","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of Platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2026.103237_bib9","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0090-8258(03)00340-8","article-title":"Gemcitabine as a single-agent treatment for ovarian cancer","volume":"90","author":"Fowler","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.jogc.2026.103237_bib10","doi-asserted-by":"crossref","first-page":"v188","DOI":"10.1093\/annonc\/mdj979","article-title":"Role of gemcitabine in ovarian cancer treatment","volume":"17","author":"Lorusso","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jogc.2026.103237_bib11","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2026.103237_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216326000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216326000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:02:13Z","timestamp":1776117733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216326000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1701216326000393"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2026.103237","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Agent Gemcitabine in Heavily Pretreated Ovarian Cancer: Experience from a Canadian Tertiary Centre","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2026.103237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc. on behalf of The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada.","name":"copyright","label":"Copyright"}],"article-number":"103237"}}